Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > 182 Mil US Entry for a 20 Billion unmet market

<< Previous

Bullboard Posts

Next >>

Post by Riverfolkon Nov 10, 2021 11:45am

165 Views

Post# 34110236

182 Mil US Entry for a 20 Billion unmet market

With Arch Biopartners Phase II trial currently having Data reviewed by a third party, the stock is currently trading at 182 mil (US) market cap with the potential to treat a 20 billion a year unmet market.

I recall posting something simular to this at 60 million, like then several will be upset they didnt buy.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing